No Data
Express News | Shenyang Xingqi Pharmaceutical: Clinical trial approval obtained for Lidocaine Hydrochloride Eye Gel.
Shenyang Xingqi Pharmaceutical (300573.SZ): The Phase IV clinical research report was obtained after the launch of Ciclosporin Eye Drops (II).
Shenyang Xingqi Pharmaceutical (300573.SZ) announced on November 12th that the company's product Cyclosporine Eye Drops (II) has recently obtained the Phase IV clinical research report on the safety and effectiveness of Cyclosporine Eye Drops (II) for the treatment of dry eyes. The company's Cyclosporine Eye Drops (II) has obtained the pharmaceutical registration certificate. As of the date of the announcement, according to the National Medical Products Administration website, the company's Cyclosporine Eye Drops (II) is the only domestically approved cyclosporine eye preparation for the treatment of dry eyes. This study is a multicenter, prospective clinical trial, with 1999 subjects participating over a period of time.
Express News | Shenyang Xingqi Pharmaceutical: The Olopatadine Hydrochloride Eye Drops obtained the pharmaceutical registration certificate.
Shenyang Xingqi Pharmaceutical (300573): Waiting patiently for low-concentration atropine to accelerate delivery, continuous improvement of ophthalmic products.
Low-concentration atropine continued to increase, the company's ophthalmic products continued to iterate, maintaining a "buy" rating. In Q1-3 2024, the company's revenue was 1.439 billion yuan (+30.27% year-on-year, all figures below are on a year-on-year basis), mainly from 0.01%.
Express News | Shenyang Xingqi Pharmaceutical: Withdrawal of pharmaceutical registration application.
Shenyang Xingqi Pharmaceutical (300573): Significant narrowing of expenses in Q3 24, Atropine completes complete follow-up experiment.
On October 29, 2024, shenyang xingqi pharmaceutical released the third quarter report of 2024, achieving revenue of 1.439 billion yuan during the reporting period, an increase of 30.27% year-on-year; net income attributable to the parent company was 0.291 billion yuan, up by 59%.
No Data
No Data